Preclinical Modeling of Combination Treatments: Fantasy or Requirement?
- 1 November 2005
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1059 (1) , 61-69
Abstract
Abstract: Combination chemotherapy is considered the “norm” in cancer chemotherapy. While the development of classical combination regimens took into account factors such as single‐agent activity, different toxicity profiles, and advantageous pharmacology of the component drugs, in the era of targeted therapies there are additional considerations such as new mechanisms of resistance due to modulation of pathway dependence. Since it is not feasible to test all of the possible combinations clinically, some method for preclinically identifying and prioritizing promising combinations is necessary. While in vivo animal models can be used for safety testing and some pharmacokinetics, even they can quickly become prohibitively resource intensive for the purpose of efficacy determinations. Therefore, factors such as biologic rationale, reliable in vitro results in more than one tumor type, achievable in vivo pharmacology, and selectivity of primary tumor cell activity become important in the evaluation of potential combination regimens.Keywords
This publication has 12 references indexed in Scilit:
- A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced CancerClinical Cancer Research, 2004
- In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell LinesClinical Cancer Research, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathwaysBlood, 2003
- Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)Oncogene, 2002
- In vitro preclinical models for a rational design of chemotherapy combinations in human tumorsCritical Reviews in Oncology/Hematology, 2001
- Basis for effective combination cancer chemotherapy with antimetabolitesPharmacology & Therapeutics, 2000
- The Hallmarks of CancerCell, 2000
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984
- Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancerCancer, 1975